Epilepsy Market Summary
The Epilepsy Market is projected to grow at a CAGR of ~7% from 2024 to 2034 across the 7MM, driven by innovative therapies such as LIBERVANT, XEN1101, COMFYDE, Lorcaserin, and Soticlestat. The market is becoming increasingly competitive, with new drug developments and recent approvals in epilepsy surgery for specific patient groups, including those with acute repetitive seizures and Lennox-Gastaut syndrome. In 2023, around 7 million diagnosed prevalent cases were reported in the 7MM, with the US accounting for 48%, EU4 and the UK 39%, and Japan 13%. Current antiepileptic drugs focus mainly on seizure control and often have side effects, offering limited benefit for refractory epilepsy patients. However, a strong pipeline targeting ion channels, receptors, and neurotransmitters may significantly shift market dynamics in the coming years.
DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast – 2034” report offers a comprehensive analysis of epilepsy, covering historical trends, forecasted epidemiology, and market dynamics across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The epilepsy treatment market is expected to experience significant growth in the coming years, fueled by advancements in therapeutic approaches and rising awareness of the disease. The pipeline features innovative candidates designed to manage acute seizures and reduce recurrence rates. The report details current treatment patterns, emerging therapies, market share of existing drugs, and the projected epilepsy market size from 2020 to 2034 across seven major markets. It also highlights treatment algorithms, key growth drivers, barriers, and unmet needs, helping to identify strategic opportunities and assess the full potential of the epilepsy market.
Discover Key Insights into the Epilepsy Market with DelveInsight's In-Depth Report @ Epilepsy Market Analysis
Key Takeaways from the Epilepsy Market Report
- Epilepsy Treatment Market Size in the 7MM was approximately USD 9 billion in 2023 and is projected to increase during the forecast period (2024–2034), with a CAGR of approximately 7%.
- The leading Epilepsy Companies such as Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
- Promising Epilepsy Therapies such as Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.
- In the 7MM, the total diagnosed prevalent cases of epilepsy were nearly 7 million in 2023, which is expected to increase at a CAGR of 0.4% by 2034.
- In the US, the total diagnosed prevalent cases of epilepsy were approximately 3.3 million in 2023, of which nearly 14% of cases were diagnosed in children and 86% in adults; the total cases of epilepsy are expected to increase by 2034.
- In 2023, the diagnosed prevalent cases in the EU4 and the UK comprised nearly 1.3 million male cases and 1.5 million female cases. These numbers are expected to rise throughout the study period.
- In 2023, among EU4 and the UK, Germany had the highest number of cases of epilepsy, i.e., 735 thousand, of which nearly 74% of the cases were focal epileptic seizures, 18% were generalized epileptic seizures, while 8% of the cases were other determined or undetermined epileptic seizures.
- Among the 7MM, in 2023, Japan accounted for the second highest diagnosed prevalent cases of epilepsy, i.e., 890 thousand cases, these cases are expected to change during the study period.
- In Japan, among the other types of epilepsies and associated diseases, the highest cases were found in drug-resistant epilepsy/refractory cases, i.e., 82 thousand followed by photosensitivity and childhood absence epilepsy with equal cases, i.e., 44 thousand, in 2023. These cases are expected to change by 2034.
Stay ahead in the Epilepsy Therapeutics Market with DelveInsight’s Strategic Report @ Epilepsy Treatment Market Outlook
Epilepsy Epidemiology
In 2023, the 7MM reported nearly 7 million diagnosed prevalent cases of epilepsy, projected to grow at a CAGR of 0.4% through 2034. The US accounted for about 3.3 million cases, with 14% in children and 86% in adults, expected to rise further. In the EU4 and the UK, there were ~1.3 million male and 1.5 million female cases, with Germany leading at 735,000—74% focal seizures, 18% generalized, and 8% other/undetermined. Japan reported 890,000 cases, the second highest in the 7MM, with drug-resistant epilepsy (82,000), photosensitivity (44,000), and childhood absence epilepsy (44,000) being the most prevalent subtypes. These numbers are anticipated to increase by 2034.
Epilepsy Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases
- Gender-specific Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases of Epilepsy Based on Seizure Type
- Diagnosed Cases of Other Types of Epilepsies and Associated Diseases
Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Prevalence
Epilepsy Treatment Market
The Epilepsy treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case. Epilepsy treatment involves various drug classes to control seizures, including sodium channel blockers (e.g., phenytoin, lamotrigine), which stabilize neuronal activity by inhibiting abnormal electrical impulses. Calcium channel blockers (e.g., ethosuximide) are effective for absence seizures, while GABAergic agents (e.g., valproate, benzodiazepines) enhance inhibitory neurotransmission to reduce seizure frequency.
The epilepsy market is primarily driven by the rising prevalence of neurological disorders, increased awareness about the disease, and advancements in diagnostic technologies and treatment options, including novel anti-epileptic drugs (AEDs) and neuromodulation therapies. Additionally, growing healthcare expenditure and government support for rare and chronic diseases contribute to market expansion. However, several barriers hinder its growth, such as the high cost of advanced treatments, limited accessibility in low-income regions, and a lack of disease awareness in rural populations. Moreover, challenges related to drug-resistant epilepsy and the side effects associated with long-term AED usage continue to impede optimal disease management.
Marketed Epilepsy Drugs
- LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
- EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals
- XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical
- AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis
Emerging Epilepsy Drugs
- XEN1101/Azetukalner: Xenon Pharmaceuticals
- Soticlestat (TAK-935): Takeda/Ovid Therapeutics
Get In-Depth Knowledge on Epilepsy Market Trends and Forecasts with DelveInsight @ Epilepsy Treatment Market
Epilepsy Market Drivers
- Rising Prevalence of Epilepsy: Nearly 7 million diagnosed prevalent cases in the 7MM, with numbers expected to grow steadily.
- Advancements in Therapies: Launch of innovative drugs like LIBERVANT, XEN1101, COMFYDE, Lorcaserin, and Soticlestat offering new treatment options.
- Expanding Treatment Landscape: Increasing approvals in epilepsy surgery and targeted therapies for subgroups such as acute repetitive seizures, partial onset seizures, and Lennox-Gastaut syndrome.
- Robust Pipeline: Ongoing research focusing on ion channels, receptors, and neurotransmitters, aiming to address refractory epilepsy and improve patient outcomes.
- Growing Awareness & Diagnosis: Improved screening and early diagnosis, particularly in developed markets, is expanding the patient pool.
Epilepsy Market Barriers
- Limited Cure Potential: Current antiepileptic drugs (AEDs) primarily control seizures without addressing the root cause of epilepsy.
- Treatment Gaps in Refractory Epilepsy: Many patients continue to experience seizures despite multiple drug combinations, leaving unmet medical needs.
- Side Effects of AEDs: Cardiovascular, respiratory, and cognitive side effects hinder patient compliance and long-term use.
- High Competition & Market Saturation: Numerous drugs with similar mechanisms make differentiation difficult for new entrants.
- Economic Burden: High cost of newer therapies and surgery limits accessibility, particularly in low- and middle-income countries.
Scope of the Epilepsy Market Report
- Coverage- 7MM
- Epilepsy Companies- Equilibre Biopharmaceuticals (Private), Eisai Co., Ltd. (TYO: 4523), Biohaven Ltd. (NYSE: BHVN), SK Biopharmaceuticals Co., Ltd. (KRX: 326030), Atnahs Pharma (Private, now Pharmanovia), Ovid Therapeutics Inc. (NASDAQ: OVID), Idorsia Ltd (SWX: IDIA), Xenon Pharmaceuticals Inc. (NASDAQ: XENE), Aquestive Therapeutics Inc. (NASDAQ: AQST), UCB S.A. (EBR: UCB), Alexza Pharmaceuticals (Private), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Takeda Pharmaceutical Company Limited (TYO: 4502), Knopp Biosciences and others.
- Epilepsy Therapies- Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.
- Epilepsy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Epilepsy Unmet Needs, KOL's views, Analyst's views, Epilepsy Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Epilepsy Market Report @ Epilepsy Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Epilepsy Market Overview at a Glance
4 Methodology of Epilepsy Epidemiology and Market
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Epilepsy Patient Journey
9 Epilepsy Epidemiology and Patient Population
10 Epilepsy Marketed Drugs
11 Epilepsy Emerging Drugs
12 Epilepsy: Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Epilepsy Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services